Related Experiment Video
Updated: May 4, 2026
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Update on new approaches in the management of hepatocellular carcinoma
Giuseppe Cabibbo1, Michela Antonucci2, Chiara Genco3
1Sezione di Gastroenterologia, Di.Bi.Mi.S., University of Palermo, Italy ; Dipartimento di Biopatologia e Metodologie Biomediche, University of Palermo, Italy.
Insights
Hepatocellular carcinoma (HCC) is a significant global health issue. Advances in surveillance and targeted therapies like sorafenib offer new hope for liver cancer patients.
Area of Science:
- Hepatology and Oncology
- Cancer Research
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally, with high prevalence in Asia-Pacific and Africa, and increasing incidence in Western nations.
- The heterogeneous nature of HCC complicates accurate survival prediction, necessitating improved diagnostic and therapeutic strategies.
- Recent progress in understanding molecular hepatocarcinogenesis opens avenues for targeted treatment approaches.
Purpose of the Study:
- To review recent advances in the prevention and therapy of Hepatocellular Carcinoma (HCC).
- To highlight the impact of targeted therapies, specifically sorafenib, in managing advanced-stage HCC.
- To discuss future research directions for personalized treatment of liver cancer.
Main Methods:
- Review of recent scientific literature on Hepatocellular Carcinoma (HCC) management.
- Analysis of clinical study outcomes for advanced-stage HCC treatments.
- Exploration of molecular mechanisms in hepatocarcinogenesis.
Main Results:
- Significant improvements in HCC prevention through enhanced surveillance of at-risk populations.
- Sorafenib represents a landmark therapy for advanced-stage HCC, demonstrating a positive impact on patient outcomes.
- Ongoing clinical trials are evaluating sorafenib as adjuvant therapy post-curative treatment for liver cancer.
Conclusions:
- Advances in surveillance and multimodal therapies have improved HCC management.
- Targeted therapies like sorafenib are transforming treatment paradigms for advanced liver cancer.
- Future research focusing on molecular classification will enable more personalized HCC treatment approaches.
Abstract:
Hepatocellular carcinoma (HCC) is a major health problem. It is currently the third cause of cancer-related death, it is highly prevalent in the Asia-Pacific region and Africa, and is increasing in Western countries. The natural history of HCC is very heterogeneous and prediction of survival in individual patients is not satisfactory because of the wide spectrum of the disease. During the past decade, major advances have been achieved in prevention, through better surveillance of patients at risk, and in therapy through better surgical and ablative therapies and multimodal treatment approaches. Moreover, the increasing knowledge of molecular hepatocarcinogenesis provides the opportunity for targeted therapies. In this setting, the impact of sorafenib on advanced-stage HCC is a landmark finding in the treatment of liver cancer. The role of sorafenib administration as adjuvant therapy after curative treatment is being evaluated in clinical studies. Future research should lead to a molecular classification of the disease and a more personalized treatment approach.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
